Zealand Pharma A/S, a biopharmaceutical company, engages in the discovery and development of peptide-based products in Denmark. Its product pipeline comprises three products in phase II clinical trials, which include AVE0010/ZP10, a glucagon-like peptide 1 for subcutaneous injection treatment of Type 2 diabetes; ZP120, a peptide intended for use in patients suffering from overload of fluid in the lungs due to acute decompensated heart failure; and Rotigaptide (ZP123), a compound for prevention of ventricular arrhythmias. The company’s product pipeline also includes ZP1846, a peptide in pre-clinical development, targeted as intravenous injection for the prevention and treatment of chemotherapy-induced diarrhoea in patients having hemopoetic stem cell transplantation. In addition, its other products include ZP1609, a preclinical development product for atrial fibrillation; and drug discovery products, such as ZP1848 for Crohn’s disease, PYY mimetic for obesity, and GAP-Oral for chronic atrial fibrillation. Zealand Pharma has collaboration with Wyeth Pharmaceuticals for the research and development of new gap junction modifying compounds targeting cardiovascular disorders. It also has a partnership agreement with Sanofi-Aventis Deutschland GmbH for the development, manufacture, and marketing of AVE0010/ZP10. The company was founded in 1998 and is based in Glostrup, Denmark.